Argus analyst David Toung raised the firm’s price target on Stryker to $380 from $335 and keeps a Buy rating on the shares. The company is seeing higher sales and margins, driven by the recovery in elective procedural volume and increased product supply, the analyst tells investors in a research note. Surgeon feedback at Stryker’s Investors Day also suggests GLP-1 weight-loss drugs may help high-BMI patients achieve eligibility criteria for joint-replacement surgeries, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYK:
- BTIG medical technology analyst to hold analyst/industry conference call
- Stryker declares a $0.80 per share quarterly dividend
- Stryker to participate in Citi’s 2024 Unplugged Medtech and Life Sciences Access Day
- Stryker price target raised to $360 from $315 at Canaccord
- Stryker price target raised to $360 from $345 at RBC Capital
